Bellevue Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bellevue Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,000	Closed	-$185K	–	226
2021 Q1	$185K	Hold	8,000	–	–	﹤0.01%	215
2020 Q4	$198K	Sell	8,000 -696,976	-99%	-$23.1M	﹤0.01%	220
2020 Q3	$29.2M	Hold	704,976	–	–	0.4%	68
2020 Q2	$33.8M	Sell	704,976 -4,000	-0.6%	-$309K	0.48%	54
2020 Q1	$44.6M	Sell	708,976 -6,200	-0.9%	-$557K	0.87%	33
2019 Q4	$88.6M	Buy	715,176 +13,000	+2%	+$1.16M	1.41%	20
2019 Q3	$46.6M	Sell	702,176 -9,627	-1%	-$646K	0.87%	34
2019 Q2	$56.6M	Buy	711,803 +694,576	+4,032%	+$62.2M	0.97%	31
2019 Q1	$1.93M	Sell	17,227 -5,921	-26%	-$647K	0.11%	110
2018 Q4	$2.33M	Sell	23,148 -1,000	-4%	-$104K	0.15%	95
2018 Q3	$3.05M	Sell	24,148 -500	-2%	-$52.9K	0.19%	94
2018 Q2	$2.07M	Sell	24,648 -7,252	-23%	-$531K	0.18%	86
2018 Q1	$1.96M	Buy	31,900 +12,500	+64%	+$753K	0.19%	80
2017 Q4	$1.13M	Buy	19,400 +10,900	+128%	+$687K	0.12%	106
2017 Q3	$493K	Hold	8,500	–	–	0.05%	124
2017 Q2	$1.03M	Hold	8,500	–	–	0.12%	101
2017 Q1	$961K	Hold	8,500	–	–	0.13%	104
2016 Q4	$924K	Sell	8,500 -5,000	-37%	-$596K	0.19%	88
2016 Q3	$2.22M	Hold	13,500	–	–	0.4%	71
2016 Q2	$1.93M	Hold	13,500	–	–	0.36%	74
2016 Q1	$1.73M	Buy	+13,500	New	+$1.59M	0.31%	82

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bellevue Group's ICPT Position: Q2 2021 in Review

Bellevue Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 8,000 shares — an estimated $185K sold.

Bellevue Group first reported a position in ICPT in Q1 2016 and held it in 21 quarters. The position peaked at $88.6M in Q4 2019. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

Bellevue Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Bellevue Group sold 8,000 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $185K.
Bellevue Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2016 and held it in 21 quarters.
Bellevue Group's Intercept Pharmaceuticals, Inc. position peaked at $88.6M in Q4 2019.
129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.